Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Alcohol Use Disorder (AUD)
NCT05646303Phase 2Active, not recruiting
- Sponsor
- Clairvoyant Therapeutics
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of psilocybin in alcohol use disorder (AUD), sponsored by Clairvoyant Therapeutics. Started May 2022; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT05646303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646303.